PT  - JOURNAL ARTICLE
AU  - Avery, Robert L
TI  - What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
AID  - 10.1136/bjophthalmol-2013-303844
DP  - 2014 Jun 01
TA  - British Journal of Ophthalmology
PG  - i7--i10
VI  - 98
IP  - Suppl 1
4099  - http://bjo.bmj.com/content/98/Suppl_1/i7.short
4100  - http://bjo.bmj.com/content/98/Suppl_1/i7.full
SO  - Br J Ophthalmol2014 Jun 01; 98
AB  - Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.